Eyenovia, Inc. (EYEN) Reports Q4 Loss, Misses Revenue Estimates
- Eyenovia, Inc. (EYEN) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.17 per share a year ago.
- 03/18/2024
|
Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
- Announced FDA approval of clobetasol propionate ophthalmic suspension 0.05% for post-operative pain and inflammation following ocular surgery
- 03/18/2024
|
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals
- EMERYVILLE, Calif. and NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Eyenovia, Inc. (Nasdaq: EYEN) announced the signing of a co-promotion agreement to commercialize prescription ophthalmic products to eyecare professionals across the U.S. Under the agreement, NovaBay will market Eyenovia's clobetasol propionate ophthalmic suspension 0.05% (“Clobetasol”), a steroid indicated for the treatment of inflammation and pain following ocular surgery, through its U.S. physician-dispensed channel. Eyenovia will market NovaBay's prescription Avenova® Antimicrobial Lid & Lash Solution through its Mydcombi and Clobetasol sales representatives strategically located across the U.S.
- 03/13/2024
|
Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th
- Company to host an investor conference call and webcast at 4:30pm EDT Company to host an investor conference call and webcast at 4:30pm EDT
- 03/11/2024
|
Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery
- Approval based on nearly 9 out of 10 patients achieving complete absence of post-surgical pain and 6 out of 10 achieving total absence of inflammation within 15 days post-ocular surgery
- 03/05/2024
|
US FDA approves Eyenovia's eye drug, Formosa Pharma says
- The U.S. Food and Drug Administration approved Eyenovia's eye drops to reduce inflammation and pain in patients who have undergone eye surgery, Formosa Pharmaceuticals said on Monday.
- 03/04/2024
|
Eyenovia: Racing Toward The Finish Line
- Eyenovia has received FDA approval for its Optejet system, which revolutionizes how eye medications are dosed, resolving limitations and adverse events caused by traditional eye droppers. The company's manufacturing facilities, including two in the USA and one in Mexico, have received FDA certification, ensuring the safety and quality of their products. Eyenovia is preparing for the official launch of its first FDA-approved product, MydCombi, and has upcoming events, including financial results and an FDA decision for another drug.
- 02/26/2024
|
Eyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing Facility
- Redwood City, California to complement Eyenovia's facility in Reno, Nevada as well as its contract manufacturer, Coastline International, to produce commercial supply of Mydcombi
- 02/13/2024
|
Eyenovia Re-Acquires Development and Commercialization Rights to MicroPine in the U.S. and Canada
- MicroPine, currently in late phase III for pediatric progressive myopia, to complement Eyenovia's commercial-stage asset, Mydcombi, as well as its pre-PDUFA candidate, APP13007
- 01/16/2024
|
7 Promising Penny Stocks With the Potential to Defy Expectations
- You know you want it. High-potential penny stocks that is.
- 12/15/2023
|
Eyenovia, Inc. (EYEN) Q3 2023 Earnings Call Transcript
- Eyenovia, Inc. (NASDAQ:EYEN ) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Glenn Garmont - LifeSci Partners, IR Michael Rowe - Chief Executive Officer John Gandolfo - Chief Financial Officer Bren Kern - Chief Operating Officer Conference Call Participants John Boyle - William Blair Raymond Wu - Ladenburg Thalmann Len Yaffe - Stoc*Doc Partners Operator Good day, ladies and gentlemen. And welcome to Eyenovia's Third Quarter of 2023 Earnings Conference Call.
- 11/13/2023
|
Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business Update
- Acquired U.S. commercial rights to APP13007, currently under FDA review for post-surgical ocular pain and inflammation, from Formosa Pharmaceuticals
- 11/13/2023
|
4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates
- Let us look at a few biotech companies, ACLX, LEGN, GRCL and EYEN, which are poised to beat third-quarter earnings estimates.
- 11/09/2023
|
Eyenovia to Report Third Quarter 2023 Results on Monday, November 13
- Company to host an investor conference call and webcast at 4:30pm EDT Company to host an investor conference call and webcast at 4:30pm EDT
- 11/06/2023
|
7 Penny Stocks To Buy Now According To Analysts, Targets Up To 751%
- The penny stock market is an enticing yet volatile landscape for investors seeking big rewards. While the chance to uncover the next hidden gem before it rockets higher is enticing.
- 11/02/2023
|
Eyenovia to Present Data on Preservative-Free Microbial Integrity of the Optejet®
- In rigorous testing, the Optejet remained contaminant-free when subjected to a microbial load that exceeds typical environmental conditions
- 10/09/2023
|
Eyenovia to Participate in Panel Discussion at Cantor Global Healthcare Conference
- NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), an ophthalmic technology company commercializing Mydcombi™ for mydriasis, preparing for regulatory approval of AP13007 for relief of pain and inflammation post ocular surgery, and incorporating its advanced Optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced that Michael Rowe, CEO, will be participating in a panel discussion at the Cantor Global Healthcare Conference, which is taking place September 26-28, 2023, in New York.
- 09/21/2023
|
Eyenovia: It Is Now Time To See Positive Results In Their Marketing Efforts
- Eyenovia has obtained the first required state pharmacy license from New York, allowing them to obtain the first commercial sale of their drug candidate MydCombi. The company has conducted training sessions in California in anticipation of obtaining licensing approval in the state, which will expand their market reach. Eyenovia has acquired the exclusive US rights to distribute and sell APP13007, an ophthalmic nanosuspension drug, from Formosa Pharmaceuticals, expanding their product portfolio.
- 08/28/2023
|
Eyenovia, Inc. (EYEN) Q2 2023 Earnings Call Transcript
- Eyenovia, Inc. (NASDAQ:EYEN ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Eric Ribner - Investor Relations Michael Rowe - Chief Executive Officer John Gandolfo - Chief Financial Officer Bren Kern - Chief Operating Officer Conference Call Participants Matthew Caufield - H.C. Wainwright Raymond Wu - Ladenburg Thalmann Operator Greetings.
- 08/13/2023
|
Eyenovia to Present at Upcoming H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference
- NEW YORK, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), an ophthalmic technology company commercializing Mydcombi™ (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5% for mydriasis and developing the Optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced management will deliver a presentation and participate in a panel discussion at the H.C. Wainwright 3rd Annual Ophthalmology Day, which is taking place virtually on August 16, 2023. Presentation and panel details are below:
- 08/09/2023
|
Eyenovia to Report Second Quarter 2023 Results on Thursday, August 10
- Company to host an investor conference call and webcast at 4:30pm EDT Company to host an investor conference call and webcast at 4:30pm EDT
- 08/07/2023
|
Eyenovia: Say Goodbye To The Eye Dropper And Welcome Optejet To The Market Place
- I will update for my readers on the background of Eyenovia. I will give the readers an explanation of the need for their business model and the advantages it offers.
- 05/27/2023
|
Eyenovia to Report First Quarter 2023 Results on Thursday, May 11
- Company to host an investor conference call and webcast at 4:30pm EDT Company to host an investor conference call and webcast at 4:30pm EDT
- 05/04/2023
|
Eyenovia, Inc. (EYEN) Q4 2022 Earnings Call Transcript
- Eyenovia, Inc. (NASDAQ:EYEN ) Q4 2022 Results Conference Call March 30, 2023 4:30 PM ET Company Participants Eric Ribner - IR Michael Rowe - CEO John Gandolfo - CFO Bren Kern - COO Operator Greetings, and welcome to the Eyenovia Fourth Quarter and Full Year 2022 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded.
- 03/30/2023
|
Eyenovia to Report Fourth Quarter and Full-Year 2022 Results on Thursday, March 30
- Company to host an investor conference call and webcast at 4:30 pm ET Company to host an investor conference call and webcast at 4:30 pm ET
- 03/23/2023
|
Eyenovia: Countdown To May 8, 2023
- I will update my previous two articles about Eyenovia. NDA accepted with no outside advisory committee formed to review their submission.
- 02/25/2023
|
Hoping Eyenovia Has The Aye Votes From The FDA In The Near Future (Rating Downgrade)
- I will update the history I've had with Eyenovia. I will share with the reader the interim and pending events since my previous article.
- 12/13/2022
|
3 Biotechnology stocks under 10 dollars to buy now
- Here are three inexpensive biotech stocks with a bright future ahead of them.
- 11/26/2022
|
Eyenovia to Present at Upcoming BTIG Ophthalmology Day
- NEW YORK, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced management will present at the BTIG Ophthalmology Day taking place virtually on November 29, 2022. Presentation details are below:
- 11/23/2022
|
Eyenovia, Inc. (EYEN) CEO Michael Rowe on Q3 2022 Results - Earnings Call Transcript
- Eyenovia, Inc. (NASDAQ:EYEN ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Eric Ribner - Investor Relations Michael Rowe - Chief Executive Officer John Gandolfo - Chief Financial Officer Conference Call Participants Leonard Yaffe - Stoc Doc Partners Operator Good day and welcome to the Eyenovia's Third Quarter 2022 Earnings Call. Today's conference is being recorded.
- 11/10/2022
|
Eyenovia to Report Third Quarter 2022 Results on Thursday, November 10
- Company to host an investor conference call and webcast at 4:30pm ET on that day Company to host an investor conference call and webcast at 4:30pm ET on that day
- 11/03/2022
|
Eyenovia to Present at the American Academy of Optometry's Annual Meeting
- NEW YORK, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs as well as out-licensing for additional indications, today announced the company will present at the 2022 American Academy of Optometry's Annual Meeting, which is taking place from October 26-29, 2022, at the at the San Diego Convention Center. Presentation details are below:
- 10/21/2022
|
Eyenovia to Present at Upcoming Healthcare Conferences
- NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced they will present at the R.W. Baird Global Healthcare Conference taking place on September 13-14, 2022 at the Intercontinental New York Barclay Hotel and the Ladenburg Thalmann Healthcare Conference taking place on September 29, 2022 at the Sofitel Hotel in New York City. Presentation details are below:
- 09/07/2022
|
Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q2 2022 Results - Earnings Call Transcript
- Eyenovia, Inc. (NASDAQ:EYEN ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Eric Ribner - Investor Relations Sean Ianchulev - Chairman Michael Rowe - Chief Executive Officer John Gandolfo - Chief Financial Officer Conference Call Participants Matt Kaplan - Ladenburg Thalmann Leonard Yaffe - Stoc Doc Partners Operator Ladies and gentlemen, greetings and welcome to the Eyenovia Second Quarter 2022 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded.
- 08/10/2022
|
Eyenovia to Report Second Quarter 2022 Results on Wednesday, August 10
- Company to host an investor conference call and webcast at 4:30pm ET on that day Company to host an investor conference call and webcast at 4:30pm ET on that day
- 08/04/2022
|
UPDATE: Eyenovia Announces Virtual 2022 Annual Meeting of Stockholders
- NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) investigational products, today announced that its Annual Meeting of Stockholders (the "Annual Meeting") will be held virtually via live webcast on Thursday, June 16, 2022 at 10:00 am EDT. Stockholders of record as of the close of business on April 18, 2022, are entitled to vote at the Annual Meeting.
- 06/09/2022
|
Eyenovia Announces Virtual 2022 Annual Meeting of Stockholders
- NEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) investigational products, today announced that its Annual Meeting of Stockholders (the "Annual Meeting") will be held virtually via live webcast on Thursday, June 16, 2022 at 10:00 am EDT. Stockholders of record as of the close of business on April 18, 2022, are entitled to vote at the Annual Meeting.
- 06/09/2022
|
Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q1 2022 Results - Earnings Call Transcript
- Eyenovia, Inc. (NASDAQ:EYEN ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Eric Ribner - Investor Relations Sean Ianchulev - President, Chief Executive Officer & Chief Medical Officer Michael Rowe - Chief Operating Officer John Gandolfo - Chief Financial Officer Conference Call Participants Tim Chiang - Northland Capital Operator Thank you for standing by, and welcome to the Eyenovia First Quarter 2022 Earnings Call. During the presentation, all participants will be in a listen only mode.
- 05/12/2022
|
Eyenovia CEO, CMO and Chairman Dr. Sean Ianchulev to Present at Eyecelerator @ American Society of Cataract and Refractive Surgery (ASCRS) 2022
- Presentation to review historic issues related to glaucoma therapies and how these may be addressed through the use of Optejet® technology Presentation to review historic issues related to glaucoma therapies and how these may be addressed through the use of Optejet® technology
- 04/20/2022
|
Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q4 2021 Results - Earnings Call Transcript
- Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q4 2021 Results - Earnings Call Transcript
- 03/28/2022
|
Eyenovia: I Can See You Better - Now
- I will share a status report on events since my original article. I will give my readers a rationale of what happened to cause the CRL delay with the FDA decision. New information and an updated timeline will be shared.
- 03/04/2022
|
8 Penny Stocks To Buy Now According To Insiders In 2022
- Penny stocks to buy now according to insiders. The post 8 Penny Stocks To Buy Now According To Insiders In 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 02/08/2022
|
Eyenovia, Inc.'s (EYEN) CEO Dr. Sean Ianchulev on Q3 2021 Results - Earnings Call Transcript
- Eyenovia, Inc.'s (EYEN) CEO Dr. Sean Ianchulev on Q3 2021 Results - Earnings Call Transcript
- 11/11/2021
|
Eyenovia, Inc. (EYEN) Reports Q3 Loss, Misses Revenue Estimates
- Eyenovia, Inc. (EYEN) delivered earnings and revenue surprises of 11.54% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 11/10/2021
|
Eyenovia: FDA Setback Is Big Opportunity For Investors
- Eyenovia is an under-the-radar ophthalmic company with a large addressable market and big opportunities ahead just received a Complete Response Letter (CRL) from the FDA for its leading drug candidate.
- 11/08/2021
|
CORRECTING AND REPLACING: Eyenovia to Report Third Quarter 2021 Results on Wednesday, November 10
- Eyenovia will release third quarter 2021 results on Wednesday, November 10, after the close. The prior version of this press release incorrectly stated that third quarter 2021 results would be released on Thursday, November 11, after the close.
- 11/05/2021
|
Eyenovia to Report Third Quarter 2021 Results on Thursday, November 11
- Company to host an investor conference call and webcast at 5:00pm ET on that day Company to host an investor conference call and webcast at 5:00pm ET on that day
- 11/04/2021
|
Eyenovia: Can You See Me Now?
- A late-stage biotech company with three products in their pipeline.
- 10/21/2021
|
Eyenovia (EYEN) Sees Hammer Chart Pattern: Time to Buy?
- Eyenovia (EYEN) has been struggling lately, but the selling pressure may be coming to an end soon.
- 09/30/2021
|
5 Best Penny Stocks To Buy Right Now According To Insiders
- 5 Penny Stocks Insiders Are Buying Right Now The post 5 Best Penny Stocks To Buy Right Now According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 08/25/2021
|
Eyenovia (EYEN) Sees Hammer Chart Pattern: Time to Buy?
- Eyenovia (EYEN) has been struggling lately, but the selling pressure may be coming to an end soon.
- 08/19/2021
|
Eyenovia's (EYEN) Management on Q2 2021 Results - Earnings Call Transcript
- Eyenovia's (EYEN) Management on Q2 2021 Results - Earnings Call Transcript
- 08/11/2021
|
Eyenovia Reports Second Quarter 2021 Financial Results
- Announced positive topline data from its Phase 3 VISION-1 study evaluating MicroLine for the treatment of presbyopia
- 08/11/2021
|
Eyenovia to Participate in Two Upcoming Investor Conferences
- NEW YORK, July 07, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced that management will present a corporate overview and host one-one-one meetings at the Ladenburg Thalmann 2021 Healthcare Conference, being held virtually July 13-14, 2021, and host one-on-meetings at the William Blair Biotech Focus Conference 2021, being held virtually July 14-15, 2021.
- 07/07/2021
|
Eyenovia: Recent MicroLine Data, October MydCombi PDUFA Date Bode Well For Value Creation
- Eyenovia is a specialty ophthalmic company that I have previously recommended. The company has three drugs in its pipeline - MydCombi, MicroLine, and MicroPine - all using Eyenovia's proprietary Optejet microdose dispenser.
- 06/02/2021
|
Eyenovia Stock Shoots Higher on Positive MicroLine Data in Late-Stage Presbyopia Study
- Eyenovia Inc (NASDAQ: EYEN) has announced topline data from its VISION-1 Phase 3 study evaluating MicroLine, for the temporary improvement of near vision in adults with presbyopia. The results will be presented at a future ophthalmic-focused medical meeting.
- 05/25/2021
|
Eyenovia Announces Positive Topline Results from VISION-1 Phase 3 Clinical Study of MicroLine for the Treatment of Presbyopia
- Primary endpoint was achieved with well-tolerated micro-array print (MAP™) safety profile
- 05/25/2021
|
Eyenovia: Still A Great Long-Term Investment In Ophthalmology
- Eyenovia: Still A Great Long-Term Investment In Ophthalmology
- 05/21/2021
|
Eyenovia's (EYEN) CEO Sean Ianchulev on Q1 2021 Results - Earnings Call Transcript
- Eyenovia's (EYEN) CEO Sean Ianchulev on Q1 2021 Results - Earnings Call Transcript
- 05/12/2021
|
Eyenovia Announces New $25 Million Credit Facility with Silicon Valley Bank
- NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the company has entered into a new $25 million credit financing facility with Silicon Valley Bank (SVB).
- 05/10/2021
|
Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q4 2020 Results - Earnings Call Transcript
- Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q4 2020 Results - Earnings Call Transcript
- 03/25/2021
|
Eyenovia Reports Fourth Quarter and Full Year 2020 Financial Results
- Announces MydCombi expected PDUFA date of October 28, 2021
- 03/25/2021
|
Eyenovia and EVERSANA Announce Partnership to Support the Potential Launch and Commercialization of MydCombi™ for Mydriasis
- NEW YORK & CHICAGO--(BUSINESS WIRE)-- #MydCombi--Eyenovia has tapped EVERSANA as exclusive distributor of its MydCombi product for pupil dilation in the U.S., pending the product's FDA approval.
- 03/23/2021
|
Eyenovia Announces Publication of MIST Pivotal Studies Demonstrating the Efficacy and Safety of its MAP™ Fixed-Combination Tropicamide-Phenylephrine Product for Mydriasis
- NEW YORK--(BUSINESS WIRE)-- #Optejet--Eyenovia's MAP™ fixed-combination pharmaceutical for pupil dilation has been shown to be safe, effective and superior in comparative study.
- 03/17/2021
|
EYEN Stock Price Increases Over 15% Pre-Market: Why It Happened
- The stock price of Eyenovia, Inc. (Nasdaq: EYEN) has increased by over 15% pre-market. This is why it happened.
- 03/02/2021
|
Eyenovia Announces FDA Acceptance of the MydCombi NDA
- NEW YORK--(BUSINESS WIRE)-- #mydriasis--FDA accepts Eyenovia's NDA for MydCombi, a unique fixed combination pupil dilation agent delivered with the Optejet. PDUFA date is expected 4Q 2021.
- 03/02/2021
|
Eyenovia to Host Key Opinion Leader Webinar on Presbyopia
- The webinar, “Presbyopia in Focus: Unlocking One of the Biggest Market Opportunities in Ophthalmology,” is scheduled for Monday, February 22, at 1:00pm ET The webinar, “Presbyopia in Focus: Unlocking One of the Biggest Market Opportunities in Ophthalmology,” is scheduled for Monday, February 22, at 1:00pm ET
- 02/16/2021
|
Circling Back On Eyenovia
- Today, we revisit a promising small ocular biopharma concern called Eyenovia for the first time in almost 18 months. The company continues to advance its pipeline and recently submitted a marketing application for approval for a new product.
- 01/03/2021
|
Eyenovia Submits New Drug Application to FDA for Pharmacologic Mydriasis with MydCombi Targeting 80 Million Patient Encounters in the U.S. Annually
- NEW YORK--(BUSINESS WIRE)-- #FDA--Eyenovia has submitted an NDA to the FDA for MydCombi, a unique fixed combination mydriatic (pupil dilation) agent delivered by the Optejet dispenser.
- 12/29/2020
|
Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q3 2020 Results - Earnings Call Transcript
- Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q3 2020 Results - Earnings Call Transcript
- 11/10/2020
|
Eyenovia to Report Third Quarter 2020 Results on Tuesday, November 10
- Company to host an investor conference call and webcast at 4:30pm ET on that day Company to host an investor conference call and webcast at 4:30pm ET on that day
- 11/05/2020
|
Eyenovia to Present Clinical Study Updates at the American Academy of Optometry Annual Meeting
- Drs. Siddarth Rathi, April Jasper to present latest analyses and updates from Eyenovia's clinical studies at the American Academy of Optometry 2020
- 10/05/2020
|
Europe Glaucoma Market and Competitive Landscape Report 2020: Pipeline, Epidemiology, Market Valuations, Drug Sales, Market Forecast, Drug Forecasts, and Market Shares 2016-2024 - ResearchAndMarkets.com
|
Eyenovia, Inc. Prices Public Offering of Common Stock
- NEW YORK, Aug. 19, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced the pricing of an underwritten public offering of 3,333,334 shares of its common stock at a price to the public of $3.60 per share. In addition, Eyenovia has granted the underwriters a 30-day option to purchase up to 500,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on August 21, 2020, subject to customary closing conditions.The gross proceeds to Eyenovia from the public offering, before deducting underwriting discounts and commissions and offering expenses payable by Eyenovia, are expected to be approximately $12 million. Eyenovia intends to use the net proceeds from the public offering, together with existing funds, to fund the continued clinical development of its product candidates, initial commercialization activities for MicroStat, and for working capital and general corporate purposes.William Blair & Company, L.L.C. is acting as sole book-running manager for the offering. National Securities Corporation is acting as the co-manager for the offering.The offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-229365) that was declared effective by the Securities and Exchange Commission (the “SEC”) on February 12, 2019. A preliminary prospectus supplement related to the offering has been filed with the SEC and a final prospectus supplement with the final terms of the offering will be filed with the SEC and will be available on the SEC’s website, located at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, or by calling (800) 621-0687, or emailing prospectus@williamblair.com.This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offer, if at all, will be made only by means of a prospectus supplement and accompanying prospectus, which are a part of the effective registration statement.About Eyenovia, Inc.Eyenovia, Inc. (NASDAQ: EYEN) is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics. Eyenovia’s pipeline is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression and mydriasis. For more Information, please visit www.eyenovia.com.Forward-Looking StatementsExcept for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the SEC. In addition, such statements could be affected by risks and uncertainties related to, among other things, the Company’s expectations regarding the closing of the public offering, its anticipated use of net proceeds from the public offering, its need to raise additional capital even after this financing, and other risks and uncertainties described in Eyenovia’s filings with the SEC. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, Eyenovia does not undertake any obligation to update any forward-looking statements.Company Contact: Eyenovia, Inc. John Gandolfo Chief Financial Officer jgandolfo@eyenoviabio.comInvestor Contact: The Ruth Group Alexander Lobo Phone: 646-536-7037 alobo@theruthgroup.com
- 08/19/2020
|
The Daily Biotech Pulse: Gilead's Filgotinib Stumbles With FDA, J&J Laps Up Momenta In $6.5B Deal, 2 IPOs
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 18)
Avenue Therapeutics Inc (NASDAQ: ATXI)
Checkmate Pharmaceuticals Inc (NASDAQ: CMPI)
DarioHealth Corp (NASDAQ:...
- 08/19/2020
|
Eyenovia, Inc. Announces Proposed Public Offering of Common Stock
- NEW YORK, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. In connection with this offering, Eyenovia expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock to be sold in the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. All of the shares in the proposed offering are to be sold by Eyenovia. Eyenovia intends to use the net proceeds from the public offering, together with existing funds, to fund the continued clinical development of its product candidates, initial commercialization activities for MicroStat, and for working capital and general corporate purposes.William Blair & Company, L.L.C. is acting as sole book-running manager for the offering.The offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-229365) that was declared effective by the Securities and Exchange Commission (the “SEC”) on February 12, 2019. A preliminary prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC’s website, located at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering, when available, may also be obtained from William Blair & Company, L.L.C., Attention: Prospectus Department, 150 North Riverside Plaza, Chicago, IL 60606, or by calling (800) 621-0687, or emailing prospectus@williamblair.com. The final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any offer or sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offer, if at all, will be made only by means of a prospectus supplement and accompanying prospectus, which are a part of the effective registration statement.About Eyenovia, Inc.Eyenovia, Inc. (NASDAQ: EYEN) is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics. Eyenovia’s pipeline is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression and mydriasis. For more Information, please visit www.eyenovia.com.Forward-Looking StatementsExcept for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the SEC. In addition, such statements could be affected by risks and uncertainties related to, among other things, market conditions, the satisfaction of customary closing conditions for the proposed offering, the Company’s expected use of the net proceeds from the public offering, its need to raise additional capital even after this financing, and other risks and uncertainties described in Eyenovia’s filings with the SEC. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, Eyenovia does not undertake any obligation to update any forward-looking statements.Company Contact: Eyenovia, Inc. John Gandolfo Chief Financial Officer jgandolfo@eyenoviabio.comInvestor Contact: The Ruth Group Alexander Lobo Phone: 646-536-7037 alobo@theruthgroup.com
- 08/18/2020
|
Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q2 2020 Results - Earnings Call Transcript
- Eyenovia, Inc. (NASDAQ:EYEN) Q2 2020 Earnings Conference Call August 12, 2020 04:30 PM ET Company Participants Alexander Lobo - The Ruth Group Sean Ianchulev - Chief Executive Officer & Chief Medical Officer Michael Rowe - Vice President, Commercial John Gandolfo - Chief Financial Officer Conference Call Participants Matt Kaplan - Ladenburg Thalmann Blair Cohen - H.C.
- 08/12/2020
|
Eyenovia Reports Second Quarter 2020 Financial Results
- NEW YORK, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today reported its financial results for the second quarter ended June 30, 2020. Second Quarter 2020 and Recent Business Highlights * Announced exclusive license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine and MicroLine in Greater China and South Korea; * Resumed recruitment of Phase III CHAPERONE study for pediatric progressive myopia; and * Preparing to submit the New Drug Application for MicroStat by the end of 2020.“Earlier this week, we entered into a license agreement with Arctic Vision, a China-based ophthalmology company, to develop and commercialize MicroPine and MicroLine for the Greater China (mainland China, Hong Kong, Macau and Taiwan) and South Korean markets. This transaction, which includes payments of up to $45.75 million in potential license and product development fees as well as commercial supply terms or royalties, expands the commercial reach of our programs into markets where the number of myopic children is estimated at greater than 240 million, more than eight times that of the United States,” commented Dr. Sean Ianchulev, Eyenovia’s Chief Executive Officer and Chief Medical Officer. “In the coming months and subject to any impacts of COVID-19, we also look forward to initiating our Phase III VISION trials for MicroLine and plan to submit our New Drug Application for MicroStat to the FDA by the end of the year.”Second Quarter 2020 Financial ReviewFor the second quarter of 2020, net loss was approximately $5.0 million, or $(0.25) per share, compared to a net loss of approximately $5.3 million, or $(0.44) per share for the second quarter of 2019.Research and development expenses totaled approximately $2.9 million for the second quarter of 2020, compared to approximately $3.6 million for the same period in 2019, a decrease of approximately 18.3%.For the second quarter of 2020, general and administrative expenses were approximately $2.1 million compared to approximately $1.8 million for the second quarter of 2019, an increase of approximately 16.3%.Total operating expenses for the second quarter of 2020 were approximately $5.0 million, compared to total operating expenses of approximately $5.4 million for the same period in 2019, a decrease of approximately 6.7%. Operating expenses for the second quarter of 2020 include approximately $0.6 million of non-cash stock compensation expense.As of June 30, 2020, the Company’s cash balance was approximately $10.2 million.Conference Call and WebcastThe conference call is scheduled to begin at 4:30pm ET on Wednesday, August 12, 2020. Participants should dial 1-866-916-2921 (United States) or 1-210-874-7771 (International) with the conference code 7380187. A live webcast of the conference call will also be available on the investor relations page of the Company's corporate website at www.eyenovia.com.After the live webcast, the event will be archived on Eyenovia’s website for one year. In addition, a telephonic replay of the call will be available until August 19, 2020. The replay can be accessed by dialing 1-855-859-2056 (United States) or 1-404-537-3406 (International) with confirmation code 7380187.About Eyenovia Eyenovia, Inc. (NASDAQ: EYEN) is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics. Eyenovia’s pipeline is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression and mydriasis. For more Information, please visit www.eyenovia.com.About MicroPine for Progressive Myopia MicroPine (atropine ophthalmic solution) is for progressive myopia, a back-of-the-eye condition commonly known as nearsightedness. Progressive myopia is estimated to affect close to 5 million children in the United States who suffer from uncontrolled axial elongation of the sclera leading to increasing levels of myopia and in some cases major pathologic changes such as retinal atrophy, macular staphylomas, retinal detachment and visual impairment. MicroPine has been developed for comfort and ease-of-use in children. Microdose administration of MicroPine is anticipated to result in low systemic and ocular drug exposure. A recent therapeutic evidence assessment and review by the American Academy of Ophthalmology indicates Level 1 (highest) evidence of efficacy for the role of low dose atropine for progressive myopia (Ophthalmology 2017;124:1857-1866; Ophthalmology 2016; 123(2) 391:399).Feasibility Dose-finding Atropine Studies: ATOM 1; ATOM 2; LAMP (Independent Collaborative Group Trials)About MicroLine for Presbyopia MicroLine is a pharmacologic treatment for presbyopia. Presbyopia is the non-preventable, age related hardening of the lens, which causes a gradual loss of the eye’s ability to focus on nearby objects and is estimated to affect nearly 113 million Americans. Current treatment options are typically device-based, such as reading glasses and contact lenses. Pilocarpine ophthalmic solution is known to constrict the pupil and improve near-distance vision by creating an extended depth of focus through its small aperture effect. Eyenovia believes that its administration of pilocarpine using the company’s high precision microdosing technology could provide a meaningful improvement in near vision while enhancing tolerability and usability.About MicroStat for Mydriasis MicroStat is Eyenovia's first-in-class fixed-combination micro-formulation product (tropicamide 1% - phenylephrine 2.5%) candidate for pharmacologic mydriasis (eye dilation), which is targeted to improve the efficiency of the estimated 80 million office-based comprehensive and diabetic eye exams performed every year in the United States, as well as the estimated 4 million pharmacologic mydriasis applications for cataract surgery. Developed for use without anesthetic, we are developing MicroStat to improve the efficacy and tolerability of pharmacologic mydriasis.About Optejet® and MicroRx Ocular Therapeutics Eyenovia's Optejet microdose formulation and delivery platform for ocular therapeutics uses high-precision piezo-print technology to deliver 6-8 μL of drug, consistent with the capacity of the tear film of the eye. We believe the volume of ophthalmic solution administered with the Optejet is less than 75% of that delivered using conventional eyedroppers, thus reducing overdosing and exposure to drug and preservatives. Eyenovia's patented microfluidic ejection technology is designed for fast and gentle ocular surface delivery, where solution is dispensed to the ocular surface in approximately 80 milliseconds, beating the ocular blink reflex. Successful use of the Optejet has been demonstrated more than 85% of the time after basic training in a variety of clinical settings compared to 40 – 50% with conventional eyedroppers. Additionally, its smart electronics and mobile e-health technology are designed to track and enhance patient compliance.Forward Looking Statements Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions, including estimated market opportunities for our product candidates. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the SEC. In addition, such statements could be affected by risks and uncertainties related to, among other things: impacts of and uncertainty related to COVID-19; fluctuations in our financial results, particularly given market conditions and the potential economic impact of COVID-19; our need to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for our product candidates; risks of our clinical trials, including, but not limited to, the costs, design, initiation and enrollment (which could still be adversely impacted by COVID-19 and resulting social distancing), timing, progress and results of such trials; the potential impacts of COVID-19 on our supply chain; the timing and our ability to submit applications for, obtain and maintain regulatory approvals for our product candidates; our estimates regarding the potential market opportunity for our product candidates; the potential advantages of our product candidates; the rate and degree of market acceptance and clinical utility of our product candidates; the potential success of our reprioritized pipeline; any cost savings related to our reprioritized pipeline; our ability to attract and retain key personnel; intellectual property risks; changes in legal, regulatory and legislative environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products; and our competitive position.
- 08/12/2020
|
The Daily Biotech Pulse: India Globalization Gets Nod For Alzheimer's Trial, Moderna's Vaccine Deal With US, Cellular Biomedicine To Go Private
- Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) * Allovir Inc (NASDAQ: ALVR) * Erytech Pharma SA (NASDAQ: ERYP) * Eyenovia Inc (NASDAQ: EYEN) (announced an exclusive collaboration and licensing agreement for MicroLine and MicroPine in Greater China and South Korea) * Evoke Pharma Inc (NASDAQ: EVOK) * Fortress Biotech (NASDAQ: FBIO)(reacted to its second-quarter results) * GENMAB A/S/S ADR (NASDAQ: GMAB) * Inari Medical Inc (NASDAQ: NARI) * iTeos Therapeutics Inc (NASDAQ: ITOS) * Kura Oncology Inc (NASDAQ: KURA) * OncoSec Medical Inc (NASDAQ: ONCS) * Orthopediatrics Corp (NASDAQ: KIDS) * Pacira Biosciences Inc (NASDAQ: PCRX) * Rocket Pharmaceuticals Inc (NASDAQ: RCKT) * Silk Road Medical Inc (NASDAQ: SILK) * Trevi Therapeutics Inc (NASDAQ: TRVI)Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 11) * Burning Rock Biotech Ltd (NASDAQ: BNR)(announced its second-quarter results) * Homology Medicines Inc (NASDAQ: FIXX)(reacted to its second-quarter results) * Legend Biotech Corp (NASDAQ: LEGN) * Nurix Therapeutics Inc (NASDAQ: NRIX)Stocks In Focus Moderna Clinches Deal With U.S. Government to Supply 100M Doses of Coronavirus Vaccine For $1.525B Moderna Inc (NASDAQ: MRNA) said it has negotiated a deal to supply the U.S. government 100 million doses of mRNA-1273, its investigational vaccine against SARS-CoV2, for up to $1.525 billion.The stock rallied 11.28% to $76.75 in after-hours trading.India Globalization Gets FDA Approval For Initiating Phase 1 Trial Of CBD Medication In Alzheimer's Patients India Globalization Capital, Inc. (NYSE: IGC) said the FDA notified on July 30 that it has authorized the company to initiate a Phase 1 human trial study for its investigational cannabinoid formulation for the treatment of patients suffering from mild to severe dementia due to Alzheimer's disease.The company said it plans to begin enrolling patients suffering from Alzheimer's-related dementia for a 12-subject safety Multiple Ascending Dose Study.The stock soared 73.62% to $1.11 in after-hours trading.Cellular Biomedicine to Go Private In Transaction Valued at $19.75/Share Cellular Biomedicine Group Inc (NASDAQ: CBMG) said it has signed a definitive merger agreement to be acquired by a consortium consisting of the company's management, led by CEO Bizuo Liu, which collectively holds about 51.5% of outstanding shares, and private equity investors, for $19.75 in cash for each outstanding share of common stock.In pre-market trading Wednesday, the stock was jumping 36.30% to $19.45.Supernus Expects Q2 Revenues to Exceed Consensus Supernus Pharmaceuticals Inc (NASDAQ: SUPN) announced preliminary second-quarter results, expecting revenues of $126.7 million, up 21% year-over-year. Analysts estimate revenues of $89.34 million.AzurRx Announces Positive Preliminary Results From Mid-phase Study of Combo Therapy In Cystic Fibrosis AzurRx BioPharma Inc (NASDAQ: AZRX) announced positive results from the first five patients in its Phase 2 combination therapy trial of MS1819 for the treatment of severe exocrine pancreatic insufficiency in patients with cystic fibrosis."In the primary efficacy analysis, patients receiving MS1819 in combination with PERT therapy achieved a clinically meaningful improvement in the coefficient of fat absorption (CFA) at each of the three dose levels, with no adverse safety events reported," AzurRx said.In after-hours trading, the stock jumped 27.38% to $1.31.Lilly, Innovent Announce Chinese Regulatory Agency's Acceptance of Application For Tyvyt Label Expansion Eli Lilly And Co (NYSE: LLY) and partner Innovent Biologics said that Chinese drug regulator agency, the National Medical Products Administration, accepted the sNDA for Tyvyt in combination with chemotherapy medication gemcitabine and platinum as first-line therapy in squamous non-small cell lung cancer.Earnings Cumberland Pharmaceuticals, Inc. (NASDAQ: CPIX) reported an increase in second-quarter net revenues from $9.4 million in 2019 to $9.6 million in 2020. Adjusted earnings per share, or EPS, increased from 5 cents to 8 cents, while analysts had estimated EPS of 3 cents.The stock gained 7.99% to $3.65 in after-hours trading.Inari Medical's second-quarter revenues fell from $27 million in 2019 to $25.4 million in 2020. The net loss per share narrowed from 17 cents to 16 cents, while analysts estimated a loss of 18 cents per share.The stock rose 6.07% to $65.90 in after-hours trading.View more earnings on IBBT2 Biosystems Inc (NASDAQ: TTOO) said its second-quarter revenues increased from $1.80 million in 2019 to $2.55 million in 2020. The loss per share narrowed from 35 cents to 9 cents, while analysts estimated a loss per share of 15 cents.The company guided full-year revenues to $18 million-$20 million, with 60 T2Dx Instrument sales contracts expected to be received in the year. Analysts, on average, estimate revenues of $14.55 million.The stock was down 11.23% to $1.66.Offerings Pacific Biosciences of California Inc (NASDAQ: PACB) said it priced its previously announced underwritten public offering of 19.43 million shares of its common stock at $4.47 per share, for raising gross proceeds of about $86.9 million. The offering is expected to close on or about August 14, 2020 subject to satisfaction of customary closing conditions.The stock added 1.79% to $4.55 in after-hours trading.Seres Therapeutics Inc (NASDAQ: MCRB) said it is commencing an underwritten registered public offering of 8 million shares of its common stock. All of the shares in the proposed offering are to be sold by the company.The stock moved up 0.80% to $20.20 in after-hours trading.Adverum Biotechnologies Inc (NASDAQ: ADVM) said it has commenced an underwritten public offering of $200 million worth of its common stock.In after-hours trading, the stock was down 3.40% to $15.06.Trevena Inc (NASDAQ: TRVN) said it intends to offer shares of its common stock in an underwritten public offering.The stock slumped 16.79% to $2.28 in after-hours trading.On The Radar Earnings Royalty Pharma plc (NASDAQ: RPRX) (before the market open) Beam Therapeutics Inc (NASDAQ: BEAM) (before the market open) Trillium Therapeutics Inc (NASDAQ: TRIL) (before the market open) Milestone Pharmaceuticals Inc (NASDAQ: MIST) (before the market open) Ideaya Biosciences Inc (NASDAQ: IDYA) (before the market open) TELA Bio Inc (NASDAQ: TELA) (after the market close) Brickell Biotech Inc (NASDAQ: BBI) (after the market close) Dare Bioscience Inc (NASDAQ: DARE) (after the market close) Biocept Inc (NASDAQ: BIOC) (after the market close) ImmuCell Corporation (NASDAQ: ICCC) (after the market close) Eyenovia Inc (NASDAQ: EYEN) (after the market close) Eton Pharmaceuticals Inc (NASDAQ: ETON) (after the market close) Thermogenesis Holdings Inc (NASDAQ: THMO) (after the market close) OpGen Inc (NASDAQ: OPGN) (after the market close) KemPharm Inc (OTC: KMPH) (after the market close) Neoleukin Therapeutics Inc (NASDAQ: NLTX) (after the market close) Salarius Pharmaceuticals Inc (NASDAQ: SLRX) (after the market close)See more from Benzinga * The Daily Biotech Pulse: Regulatory Setback For Fennec Pharma, Ligand To Buy Pfenex, Inovio Says Phase 2/3 Coronavirus Vaccine Study Starts In September * The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings * The Daily Biotech Pulse: Novavax Vaccine Deals, Trevena Awaits FDA Decision, 2 IPOs(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 08/12/2020
|
Eyenovia and Arctic Vision Announce Exclusive Collaboration and License Agreement to Develop and Commercialize MicroPine and MicroLine in Greater China and South Korea
- Eyenovia Eligible to Receive up to a Total of $45.75 million in Upfront Payments and Development and Commercialization Milestones and Development Costs Arctic Vision to Lead Expansion of Novel Approach to Treating Myopia and Presbyopia in Greater China and South KoreaNEW YORK and SHANGHAI, China, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics and Arctic Vision, a clinical stage biotech company focused on developing and commercializing innovative ophthalmology therapies in China and Asia, today announced that they have entered into an exclusive license agreement for Arctic Vision to develop and commercialize MicroPine for the treatment of progressive myopia and MicroLine for the treatment of presbyopia in Greater China (mainland China, Hong Kong, Macau and Taiwan) and South Korea.Under the terms of the agreement, Eyenovia may receive up to a total of $45.75 million in upfront payments as well as additional payments, based on various development and regulatory milestones, including the initiation of clinical research and approvals in Greater China and South Korea, and development costs. In addition, Arctic Vision will purchase its supply of MicroPine and MicroLine from Eyenovia or, for such products not supplied by Eyenovia, pay Eyenovia a mid-single digit percentage royalty on net sales of such products, subject to certain adjustments. Eyenovia will pay a mid-double digit percentage of such payments, royalties, or net proceeds of such supply to its Asian licensee pursuant to the arrangement by which Eyenovia reacquired rights to such products in Greater China and South Korea from the original licensee.“This licensing agreement with Arctic Vision grows our commercial reach to address some of the largest progressive myopia markets in the world,” commented Dr. Sean Ianchulev, Eyenovia’s Chief Executive Officer and Chief Medical Officer. "With the continued validation of our therapeutic approach, the agreement also provides non-dilutive capital to further support our planned launch of MicroStat in the United States next year, as well as the ongoing development of our late stage ophthalmology pipeline including MicroPine for progressive myopia and MicroLine for improvement in near vision.”Eddy (Hoi Ti) Wu, Ph.D., Founder and CEO, Arctic Vision added, “Eyenovia is a leader in the field of novel microdosing technology to treat myopia and presbyopia and we are committed to accelerating the development of MicroPine and MicroLine in Greater China and South Korea. In Asia, it is estimated that up to 50% of children in some regions are myopic, and the figure is increasing. On the other end of the spectrum, many people over the age of 40 are gradually suffering from age related presbyopia, which is currently corrected exclusively with medical devices or surgery-based modalities. We believe MicroPine and MicroLine have the potential to address the needs unmet by conventional eye drops and can play an important role in growing Arctic Vision’s innovative pipeline. Through this new partnership, we believe we can lead the Chinese ophthalmology market into the future.”About MicroPine for Progressive Myopia MicroPine (atropine ophthalmic solution) is for progressive myopia, a back-of-the-eye condition commonly known as nearsightedness. Progressive myopia is estimated to affect close to 5 million children in the United States who suffer from uncontrolled axial elongation of the sclera leading to increasing levels of myopia and in some cases major pathologic changes such as retinal atrophy, macular staphylomas, retinal detachment and visual impairment. MicroPine has been developed for comfort and ease-of-use in children. Microdose administration of MicroPine is anticipated to result in low systemic and ocular drug exposure. A recent therapeutic evidence assessment and review by the American Academy of Ophthalmology indicates Level 1 (highest) evidence of efficacy for the role of low dose atropine for progressive myopia (Ophthalmology 2017;124:1857-1866; Ophthalmology 2016; 123(2) 391:399).Feasibility Dose-finding Atropine Studies: ATOM 1; ATOM 2; LAMP (Independent Collaborative Group Trials)About MicroLine for Presbyopia MicroLine is a pharmacologic treatment for presbyopia. Presbyopia is the non-preventable, age related hardening of the lens, which causes a gradual loss of the eye’s ability to focus on nearby objects and is estimated to affect nearly 113 million Americans. Current treatment options are typically device-based, such as reading glasses and contact lenses. Pilocarpine ophthalmic solution is known to constrict the pupil and improve near-distance vision by creating an extended depth of focus through its small aperture effect. Eyenovia believes that its administration of pilocarpine using the company’s high precision microdosing technology could provide a meaningful improvement in near vision while enhancing tolerability and usability.About Optejet® and MicroRx Ocular Therapeutics Eyenovia's Optejet microdose formulation and delivery platform for ocular therapeutics uses high-precision piezo-print technology to deliver 6-8 μL of drug, consistent with the capacity of the tear film of the eye. We believe the volume of ophthalmic solution administered with the Optejet is less than 75% of that delivered using conventional eyedroppers, thus reducing overdosing and exposure to drug and preservatives. Eyenovia's patented microfluidic ejection technology is designed for fast and gentle ocular surface delivery, where solution is dispensed to the ocular surface in approximately 80 milliseconds, beating the ocular blink reflex. Successful use of the Optejet has been demonstrated more than 85% of the time after basic training in a variety of clinical settings compared to 40 – 50% with conventional eyedroppers. Additionally, its smart electronics and mobile e-health technology are designed to track and enhance patient compliance.About Eyenovia Eyenovia, Inc. (NASDAQ: EYEN) is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics. Eyenovia’s pipeline is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression and mydriasis. For more Information, please visit www.eyenovia.com.About Arctic Vision Arctic Vision is a China-based clinical stage specialty ophthalmology company with a leading portfolio of breakthrough technologies. The company’s vision is to address ophthalmology’s unmet needs through innovative therapies in China, Asia and globally. Arctic Vision is established by top-tier life sciences investors, and led by an elite team of ophthalmic industry veterans with substantial and compelling China and global experiences in R&D and commercialization of eye care products. For more information, please visit www.arcticvision.com.Forward Looking Statements Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions, including estimated market opportunities in the United States for our product candidates. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the SEC. In addition, such statements could be affected by risks and uncertainties related to, among other things: our ability to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for our product candidates; our estimates regarding the potential market opportunity for our product candidates; the potential advantages of our product candidates; the rate and degree of market acceptance and clinical utility of our product candidates; impacts of and uncertainty related to COVID-19; fluctuations in our financial results, particularly given market conditions and the potential economic impact of COVID-19; our need to raise additional money to fund our operations for at least the next 12 months as a going concern; the potential impacts of COVID-19 on our supply chain; risks of our clinical trials, including, but not limited to, the costs, design, initiation and enrollment (which could still be adversely impacted by COVID-19 and resulting social distancing), timing, progress and results of such trials; the timing and our ability to submit applications for, obtain and maintain regulatory approvals for our product candidates; the potential success of our reprioritized pipeline; any cost savings related to our reprioritized pipeline; our ability to attract and retain key personnel; intellectual property risks; changes in legal, regulatory and legislative environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products; and our competitive position. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, we do not undertake any obligation to update any forward-looking statements.Eyenovia Contact: Eyenovia, Inc.
- 08/11/2020
|
The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earnings
- Biotech stocks advanced in the week ended Aug. 7, buoyed by multiple catalysts. Aside from the broader market strength, mostly positive earnings and continuing coronavirus...
- 08/09/2020
|
Eyenovia Announces Conference Call and Webcast for Second Quarter 2020 Financial Results
- NEW YORK, July 29, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the Company will release financial results for the second quarter ended June 30, 2020 on Wednesday, August 12, 2020, after the market closes. Following the release, Dr. Sean Ianchulev, Chief Executive Officer and Chief Medical Officer, John Gandolfo, Chief Financial Officer, and Michael Rowe, Vice President, Commercial will host a conference call to review the financial results. The conference call is scheduled to begin at 4:30pm ET on Wednesday, August 12, 2020. Participants should dial 1-866-916-2921 (United States) or 1-210-874-7771 (International) with the conference code 7380187. A live webcast of the conference call will also be available on the investor relations page of the Company's corporate website at www.eyenovia.com.After the live webcast, the event will be archived on Eyenovia’s website for one year. In addition, a telephonic replay of the call will be available until August 19, 2020. The replay can be accessed by dialing 1-855-859-2056 (United States) or 1-404-537-3406 (International) with confirmation code 7380187.About Eyenovia Eyenovia, Inc. (NASDAQ: EYEN) is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAPTM) therapeutics. Eyenovia’s pipeline is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression and mydriasis. For more Information, please visit www.eyenovia.com.Company Contact: Eyenovia, Inc. John Gandolfo Chief Financial Officer jgandolfo@eyenoviabio.com Investor Contact: The Ruth Group Alexander Lobo Phone: 646-536-7037 alobo@theruthgroup.com
- 07/29/2020
|
3 “Strong Buy” Healthcare Stocks Under $5 That Could Double (Or More)
- The healthcare sector took its place among the winners this year, rising 21%, compared to the S&P 500’s 0.5% growth. The bottom-line for investors? Wall Street’s focus is on the healthcare space, locking in on biotechs in particular.It should be noted that these stocks are risky in nature, with their shares prone to explosive movements on account of only a few key catalysts like updates on clinical studies or regulatory approvals. The good news is that a favorable outcome can drive massive share price appreciation. However, the bad news is that the opposite holds true.Given this volatility, it can be difficult to gauge which healthcare stocks are primed to outperform. That’s where Wall Street analysts come in.Using TipRanks’ database, we identified three trading for less than $5 per share that not only earned a “Strong Buy” consensus rating from the analyst community, but also boasts triple-digit upside potential.Leap Therapeutics Inc. (LPTX)Developing innovative monoclonal antibodies, Leap Therapeutics targets key cellular pathways that enable cancer to grow and proliferate, known as cancer cell signaling, and pathways that help the body’s immune system identify and treat cancer. Given its promising technology and $1.77 share price, the company has been impressing analysts left and right.Calling LPTX a “diamond in the rough”, Piper Sandler analyst Tyler Van Buren points to the initial results of its lead candidate, DKN-01 (anti-DKK1 mAb), as a single agent and combination therapy in highly pretreated esophagogastric and gynecologic cancer patients as contributing to his optimistic stance. Looking at the monotherapy cohorts, the candidate generated a complete response (CR) and three partial responses (PRs), which demonstrates the mechanism is active, in Van Buren’s opinion. He added, “In combination with PD-1 or chemotherapy, DKK1-high patients or those with Wnt-activating mutations derived significantly greater clinical benefit compared to DKK1-low patients.”What are the implications of the data? Van Buren argued, “We believe the anti-DKK1 approach has a clear biological rationale, DKK1 expression is a promising biomarker and prospectively-defined indicator for poor prognosis, and the fact that DKN-01 has monotherapy activity is impressive and unique. Considering the data generated to date, we believe DKN-01 has the potential to improve outcomes in historically hard-to-treat solid tumor types.”Adding to the good news, LPTX counts BeiGene as a partner in the advancement of DKN-01 in combination with tislelizumab (PD-1) in esophagogastric cancer. There’s also an ongoing Phase 2 DKN-01/chemo combo study in 1L gynecologic cancers, with data slated for release by year end, and several ISTs in other difficult tumor types are progressing on schedule.To this end, should the therapy ultimately receive approval, Van Buren believes DKN-01 could launch in the U.S. in 2025 in the r/r setting and in the 1L setting in 2026, with the estimate for peak sales landing at roughly $900 million in gastric cancer.To this end, Van Buren rates LPTX an Overweight (i.e. Buy) along with a $6 price target. Should the target be met, a twelve-month gain in the shape of a whopping 240% could be in store. (To watch Van Buren’s track record, click here) Judging by the consensus breakdown, other analysts also like what they’re seeing. 3 Buys and no Holds or Sells add up to a Strong Buy consensus rating. Based on the $6.33 average price target, the upside potential comes in at 259%. (See LPTX stock analysis on TipRanks)Corvus Pharmaceuticals (CRVS)Focused on the development of medicines with precise mechanisms of action, Corvus Pharmaceuticals wants to improve the lives of patients with difficult-to-treat cancers like refractory renal cell carcinoma and non-small cell lung cancer. Currently going for $4.09 apiece, several members of the Street think that the share price presents investors with an opportunity to get in on the action.While boasting expertise in oncology, H.C. Wainwright analyst Swayampakula Ramakanth reminds investors that the company is also targeting COVID-19. On July 7, CRVS unveiled an additional clinical program for CPI-006, its patented monoclonal antibody targeting CD73, and initiated a Phase 1 study to evaluate the drug in COVID-19 patients. The study follows up the release of evidence that supports CPI-006’s immunostimulatory activity, with the candidate also producing strong results in a COVID-19 patient who is a cohort member in the Phase 1 study evaluating CPI-006 as a treatment for advanced tumors.Taking a closer look at the early results, after dosing, B cells were activated, resulting in surface marker changes consistent with B cell differentiation and isotype class switching. “Separately, in cancer patients, CPI-006 treatment led to elevated serum levels of memory B cells, the cells responsible for long-term immunity,” Ramakanth noted.The analyst added, “In an ongoing Phase 1 study with CPI-006 as a treatment for advanced tumors, a patient with advanced metastatic non-small cell lung cancer who was confirmed positive for COVID-19 infection post CPI-006 treatment developed high titers of anti-SARS-CoV-2 IgG and IgM of 1:102,400 and 1:3,200, respectively, within six weeks post a single dose. The patient tested negative for the virus at the six-week time point... Additionally, serum levels of memory B cells in this COVID-19 patient increased to 30% of total B cell count, from 16%, which is consistent with the levels seen in cancer patients treated with CPI-006.”All of the above led Ramakanth to conclude that the candidate has significant potential as a COVID-19 treatment. Therefore, if the COVID-19 study, which is designed to enroll up to 30 COVID-19 patients with mild to moderate symptoms, meets the required endpoints, a randomized study of CPI-006 will be initiated. These results could potentially support a BLA filing for FDA approval, in Ramakanth’s opinion.In line with his optimistic take, Ramakanth stayed with the bulls. In addition to reiterating a Buy recommendation, he left the price target at $10, suggesting 145% upside potential. (To watch Ramakanth’s track record, click here) The bulls have it on this one. Out of 3 total reviews published in the last three months, all 3 analysts rated the stock a Buy. So, CRVS gets a unanimous Strong Buy consensus rating. Given the $8.33 average price target, shares could soar nearly 100% in the next twelve months. (See Corvus stock analysis on TipRanks)Eyenovia Inc. (EYEN)Last but not least, we come across Eyenovia, which uses its cutting-edge microdosing technology to develop treatments for conditions that affect the eyes. With some of its clinical activities back up and running, its $2.70 share price could reflect an attractive entry point.Recently, EYEN revealed that it had resumed patient enrollment at nearly all clinical sites for its Phase 3 CHAPERONE study, after the COVID-19 pandemic forced the company to temporarily halt enrollment. The study is evaluating the safety and efficacy of MicroPine for the reduction of progressive myopia using its atropine topical micro-formulation delivered by the Optejet dispenser.Even though the health crisis spurred headwinds, the follow-up and monitoring of previously-enrolled CHAPERONE patients via telemedicine and remote monitoring processes were able to progress.Writing for Ladenburg, analyst Matthew Kaplan pointed out, “The company has shared positive preliminary usability data of the Optejet, where patients as young as 5 years old were able to self-administer treatment. Importantly, EYEN has initiated strategies to maintain the integrity of the data for patients already enrolled in the trial with the institution of virtual monitoring.” Additionally, he argues that top-line data could potentially still come by 2023.On top of this, the company’s pipeline includes its MicroLine program designed for the presbyopia (farsightedness) indication. Currently, there aren’t any FDA approved treatments available for the condition, and the standard of care is reading glasses or contact lenses. While the program’s two Phase 3 studies have been delayed thanks to COVID-19, management believes it will be able to initiate the trials in 2020. Kaplan added, “Initial market research confirmed the company’s commercial assumptions that high-income middle-aged subjects would be receptive to MicroLine.”If that wasn’t enough, its MicroStat product has demonstrated compelling results in both the MIST-1 and MIST-2 studies. As a result, EYEN plans to assess the manufacturing and stability batches as well as submit an NDA during 2H20. “With Eyenovia’s plan to price MicroStat on parity to the current eye drops based on their market research, and with an estimated 80 million dilated eye exams and ~4 million surgeries requiring dilation performed each year, we believe it could represent a significant market opportunity for MicroStat,” Kaplan commented.As Kaplan sees the company’s strategy as being very much intact, the deal is sealed. To this end, he kept a Buy rating and $19 price target on the stock. This target conveys his confidence in EYEN’s ability to climb 604% higher in the next year. (To watch Kaplan’s track record, click here) The rest of the Street agrees with Kaplan. Only Buy ratings, 3, in fact, have been issued in the last three months, so the consensus rating is a Strong Buy. At $13, the average price target puts the upside potential at 381%. (See EYEN stock-price forecast on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
- 07/20/2020
|
Ocular Therapeutix Is A Good Value Based On Its Strong Technology Platform (NASDAQ:OCUL)
- Ocular Therapeutix already has one marketed product and several promising pipeline therapies using its novel implant technology for the treatment of eye diseases.
- 07/09/2020
|
Eyenovia Resumes Recruitment of Phase III CHAPERONE Study for Progressive Myopia
- Eyenovia, Inc. (EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the Company has resumed patient enrollment for its Phase III CHAPERONE study for the treatment of progressive myopia, following a temporary pause due to the COVID-19 pandemic. The study is investigating the safety and efficacy of MicroPine for the reduction of progressive myopia using Eyenovia’s proprietary atropine topical micro-formulation delivered by the Optejet™ dispenser.
- 06/30/2020
|
Eyenovia, Inc. Announces Adjournment of 2020 Annual Meeting of Stockholders to June 30, 2020 and Change to a Virtual Meeting Format
- Eyenovia, Inc. (EYEN) a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that it adjourned its 2020 Annual Meeting of Stockholders (the “Annual Meeting”) originally scheduled to be held on June 11, 2020 at 9:00 a.m., EDT to June 30, 2020 at 9:00 a.m., EDT, to be conducted in a virtual-only format, via live webcast (the “Adjourned Annual Meeting”). Stockholders will not be able to physically attend the Adjourned Annual Meeting in person. Stockholders at the close of business on the record date, April 15, 2020, are entitled to participate in the Adjourned Annual Meeting by means of remote communication.
- 06/11/2020
|
Eyenovia Announces Intention to Adjourn 2020 Annual Meeting of Stockholders to June 30, 2020 and Change to a Virtual Meeting Format
- Eyenovia, Inc. (EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that it intends to convene and immediately adjourn its 2020 Annual Meeting of Stockholders (the “Annual Meeting”) scheduled to be held on June 11, 2020 at 9:00 a.m., EDT to June 30, 2020 at 9:00 a.m., EDT, and that the adjourned meeting will be conducted exclusively in a virtual-only format by means of remote communication. Stockholders and their proxy holders will not be able to physically attend the adjourned Annual Meeting in person, however, stockholders and their proxy holders may be deemed present in person and will be able to vote and ask questions during the adjourned Annual Meeting by means of remote communication through the online platform.
- 06/05/2020
|
Hollywood Rewind | Red Eye: Beware of delayed flights and attractive strangers!
- Red Eye leans towards the rom-com tropes in the first few minutes of the film, and it really throws you off the scent for some time until we see our leads seated next to each other in a plane.
- 05/30/2020
|
Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q1 2020 Results - Earnings Call Transcript
- Eyenovia, Inc. (NASDAQ:EYEN) Q1 2020 Earnings Conference Call May 13, 2020 16:45 ET Company Participants Tram Bui - Senior Vice President, Investor Relations Se
- 05/14/2020
|
Eyenovia Reports First Quarter 2020 Financial Results
- NEW YORK, May 13, 2020 -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its.
- 05/13/2020
|
The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 12)
Acceleron Pharma Inc (NASDAQ...
- 05/13/2020
|
The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight
- The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB)...
- 05/10/2020
|
8-K: EYENOVIA, INC.
- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________ FORM 8-K __________________ CURRENT REPORT Pursuant to Section 13...
- 05/09/2020
|
Eyenovia Announces Conference Call and Webcast for First Quarter 2020 Financial Results
- NEW YORK, May 06, 2020 -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its.
- 05/06/2020
|
Will Eyenovia Continue to Surge Higher?
- As of late, it has definitely been a great time to be an investor Eyenovia
- 04/22/2020
|
Daily Insider Ratings Round Up 3/25/20
- Tables of the top insider purchases and sales filed with the SEC on 3/25/20, based on dollar value. Dollar values often do not equate with significance when it
- 03/27/2020
|
Insider Buying: Stuart Grant Just Spent US$1.9m On Eyenovia, Inc. (NASDAQ:EYEN) Shares
- Eyenovia, Inc. (NASDAQ:EYEN) shareholders (or potential shareholders) will be happy to see that insider Stuart Grant...
- 03/26/2020
|
Eyenovia (EYEN) Receives a Hold from Oppenheimer
- Oppenheimer analyst Esther Rajavelu maintained a Hold rating on Eyenovia (EYEN) today. The company's shares closed last Monday at $2.34. According to
- 03/26/2020
|
Eyenovia (EYEN) Receives a Hold from Oppenheimer
- Oppenheimer analyst Esther Rajavelu maintained a Hold rating on Eyenovia (EYEN – Research Report) today. The company’s shares closed last
- 03/26/2020
|
Eyenovia Reports Fourth Quarter and Full Year 2019 Financial Results
- NEW YORK, March 25, 2020 -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its.
- 03/25/2020
|
Eyenovia, Inc. to Host Earnings Call
- NEW YORK, NY / ACCESSWIRE / March 25, 2020 / Eyenovia, Inc. (NASDAQ:EYEN) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 25, 2020 at 4:30 PM Eastern ...
- 03/25/2020
|
The Daily Biotech Pulse: T2 Biosystems Licenses COVID-19 Test, Immuron CEO Steps Down
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 24) * BELLUS Health Inc (NASDAQ: BLU) * Global Cord Blood Corp (NYSE: CO) * Thermogenesis Holdings Inc (NASDAQ: THMO)(reacted to its fourth-quarter
- 03/25/2020
|
Eyenovia, Inc. Announces Closing of Approximately $6.0 Million Private Placement
- Eyenovia, Inc. (EYEN) a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print technology, announced that today it closed its previously announced private placement of units which resulted in gross proceeds of $5,984,931 before deducting the placement agent's fees and estimated offering expenses. Each unit consists of (i) one share of common stock, par value $0.0001 per share, (ii) a one-year warrant to purchase 0.5 of a share of common stock, and (iii) a five-year warrant to purchase 0.75 of a share of common stock.
- 03/24/2020
|
Eyenovia, Inc. Announces Approximately $6.0 Million Private Placement
- Eyenovia, Inc. (EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print technology, today announced that it has received subscriptions for a private placement in the amount of approximately $6.0 million of units at a price to the public of $2.21425 per unit. Each unit consists of (i) one share of common stock, par value $0.0001 per share, (ii) a one-year warrant to purchase 0.5 of a share of common stock, and (iii) a five-year warrant to purchase 0.75 of a share of common stock. The proceeds of the offering are expected to be used, together with other available funds, for the MicroLine and MicroPine clinical studies, to advance MicroStat’s new drug application, and for working capital and general corporate purposes.
- 03/23/2020
|
The Week Ahead In Biotech: Bristol-Myers, Rockwell Medical Await FDA Decisions, COVID-19 Updates In Focus
- Benzinga is covering every angle of how the coronavirus affects the financial world. For daily updates, sign up for our coronavirus newsletter.
Biotech stocks went on a roller...
- 03/22/2020
|
The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 19.) * Biomerica, Inc. (NASDAQ: BMRA) * Centogene NV (NASDAQ: CNTG) * Gilead Sciences, Inc. (NASDAQ: GILD) * Imara Inc (NASDAQ: IMRA) * Regeneron Pharmaceuticals
- 03/20/2020
|
The Daily Biotech Pulse: Mylan Ramps Up Manufacturing Of Potential COVID-19 Drug, Lexicon Stops Study Early, Masimo To Buy German Ventilation Company
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 19.)
Biomerica, Inc. (NASDAQ...
- 03/20/2020
|
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 18)
Biomerica, Inc. (NASDAQ...
- 03/19/2020
|
The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 12.)
Masimo...
- 03/13/2020
|
Eyenovia Announces Conference Call and Webcast for Fourth Quarter and Full-Year 2019 Financial Results
- NEW YORK, March 11, 2020 -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its.
- 03/11/2020
|
Safe Harbor Marinas buys two more marinas on Chesapeake Bay
- One of your neighbors posted in Neighbor News. Click through to read what they have to say. (The views expressed in this post are the author’s own.)
- 03/10/2020
|
Eyenovia to Participate in Two Upcoming Investor Conferences
- NEW YORK, March 04, 2020 -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its.
- 03/04/2020
|
How Does Eyenovia, Inc. (NASDAQ:EYEN) Affect Your Portfolio Volatility?
- If you own shares in Eyenovia, Inc. (NASDAQ:EYEN) then it's worth thinking about how it contributes to the volatility...
- 02/17/2020
|
Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?
- Zoetis Inc. (ZTS) will provide financial numbers for fourth-quarter 2019 and pipeline updates on Feb 13.
- 02/10/2020
|
Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?
- Zoetis Inc. (ZTS) will provide financial numbers for fourth-quarter 2019 and pipeline updates on Feb 13.
- 02/10/2020
|
Bluebird up 2% premarket on two new bullish calls
- Bluebird bio (NASDAQ:BLUE) initiated with Buy rating and $120 (56% upside) price target at Bank of America. Upgraded to Outperform with a $100 price target at Evercore ISI. Shares up 2% premarket.Cent
- 02/03/2020
|
Have Insiders Been Buying Eyenovia, Inc. (NASDAQ:EYEN) Shares?
- We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is...
- 12/19/2019
|
Eyenovia Expands Scientific Advisory Board with Two Experts in Optometry
- Eyenovia, Inc. (EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that Professor Mark Bullimore, PhD and April Jasper, OD have joined Eyenovia’s Scientific Advisory Board. “We are very pleased to welcome two highly accomplished and respected optometrists to our Scientific Advisory Board,” commented Dr. Sean Ianchulev, Eyenovia’s Chief Executive Officer and Chief Medical Officer.
- 12/19/2019
|
Eyenovia, Inc. (EYEN) Shares March Higher, Can It Continue?
- As of late, it has definitely been a great time to be an investor Eyenovia, Inc. (EYEN).
- 12/02/2019
|
All You Need to Know About Eyenovia, Inc. (EYEN) Rating Upgrade to Strong Buy
- Eyenovia, Inc. (EYEN) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 11/27/2019
|
Eyenovia Reports Third Quarter 2019 Financial Results
- NEW YORK, Nov. 13, 2019 -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its.
- 11/13/2019
|
Can European Buyouts Aid Canopy Growth's (CGC) Q2 Earnings?
- Canopy Growth (CGC) acquires a number of European companies to expand its production base across a region that promises great opportunities.
- 11/12/2019
|
What's in Store for Applied Materials' (AMAT) Q4 Earnings?
- Applied Materials' (AMAT) technology leadership position and strong product line in Display and Services are likely to reflect on fiscal fourth-quarter results.
- 11/12/2019
|
Can Cannabis Therapy Drive Canopy Growth's (CGC) Q2 Earnings?
- A series of acquisitions is expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal second quarter.
- 11/11/2019
|
Overstock (OSTK) to Report Q3 Earnings: What's in Store?
- Overstock's (OSTK) third-quarter results are likely to reflect strength across retail and blockchain businesses.
- 11/11/2019
|
